This paper is in the following e-collection/theme issue:

Cyberpharmacies (58) Infodemiology and Infoveillance (1558) Drug Repurposing and Off-Label Use (28) Pharmacology and Pharmaceutics (111) Methods and Instruments in Medical Informatics (189) Obesity (117) Obesity and Nutrition as Public Health Problem (397) Harm Reduction Approaches (39)

Published on in Vol 26 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/65440, first published .
Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study

Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study

Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study

Authors of this article:

Amir Reza Ashraf1 Author Orcid Image ;   Tim Ken Mackey2 Author Orcid Image ;   Róbert György Vida1 Author Orcid Image ;   Győző Kulcsár3 Author Orcid Image ;   János Schmidt4 Author Orcid Image ;   Orsolya Balázs1 Author Orcid Image ;   Bálint Márk Domián1 Author Orcid Image ;   Jiawei Li5 Author Orcid Image ;   Ibolya Csákó6 Author Orcid Image ;   András Fittler1 Author Orcid Image
Article Authors Cited by (11) Tweetations (9) Metrics

Journals

  1. Turnock L, Hearne E, Lazuras L. Made in China: The international supply of illicit Semaglutide and weight-loss medicines online. Emerging Trends in Drugs, Addictions, and Health 2025;5:100169 View
  2. O'Keefe J, Franco W, O'Keefe E. Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy. Progress in Cardiovascular Diseases 2025;89:102 View
  3. Basdevant A. Inhibiteurs de l’appétit et prévention de l’obésité. Médecine des Maladies Métaboliques 2025;19(6):492 View
  4. Miot H. Commentary on “Facial Remodeling Addressing Fat Loss and Skin Sagging With Poly-l-Lactic Acid SCA and Hyaluronic Acid Filler After Semaglutide-Associated Prescriptive Weight Loss”. Dermatologic Surgery 2025;51(10):1005 View
  5. Turnock L, Hearne E, Germain J, Hirst M, Townshend H, Lazuras L. Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction. International Journal of Drug Policy 2025;142:104854 View
  6. Altabas V, Orlović Z, Baretić M. Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review. Diabetology 2025;6(6):52 View
  7. Mackey T, Nali M, Larsen M, Li Z, Li J, Yang J. Online Availability of Diamond Shruumz Before and After FDA Recall Initiation: Qualitative Assessment and Simulated Test Purchasing. Journal of Medical Internet Research 2025;27:e64820 View
  8. Kim K, Park J, Choi H. Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects. Annals of Pediatric Endocrinology & Metabolism 2025;30(4):165 View
  9. Rušić D, Durdov T, Jadrijević I, Šešelja Perišin A, Leskur D, Božić J, Klusmeier M, Bukić J. Semaglutide in the Real World: Attitudes of the Population. Pharmacy 2025;13(5):128 View
  10. Antonacci G, Bortignon E, Bolognesi M, Piano S, Cadore A, Camuffo L, Venturini F, Faoro S, Favretto D, Romano A, Mengato D. Hypoglycaemic coma induced by a falsified semaglutide product: a case report. European Journal of Hospital Pharmacy 2025:ejhpharm-2025-004656 View
  11. Turnock L, Germain J, Hirst M, Hearne E. Off-label Semaglutide & GLP-1 weight-loss medicine use for anti-ageing: A Netnography of older bodybuilders’ experiences and understandings. Performance Enhancement & Health 2026;14(1):100355 View